Compare PBYI & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBYI | ROMA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 520.6M |
| IPO Year | 2011 | 2022 |
| Metric | PBYI | ROMA |
|---|---|---|
| Price | $10.44 | $6.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 339.7K | 46.4K |
| Earning Date | 11-05-2026 | 07-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $27,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.33 | N/A |
| P/E Ratio | $132.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.58 | $1.16 |
| 52 Week High | $11.50 | $11.77 |
| Indicator | PBYI | ROMA |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 40.11 |
| Support Level | $9.04 | $6.01 |
| Resistance Level | $11.50 | $8.53 |
| Average True Range (ATR) | 0.46 | 0.80 |
| MACD | -0.04 | -0.14 |
| Stochastic Oscillator | 39.77 | 42.72 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Roma Green Finance Ltd is a professional specialist in the provision of environmental, social and governance (ESG), sustainability and climate change related advisory services through its operating subsidiaries in Hong Kong and Singapore. Its services include Sustainability Program Development, ESG Reporting, Corporate Governance and Risk Management, Climate Change Strategies and Solutions, Environmental Audit, ESG Rating Support and Shareholder Communication, and Education and Training. It operates in one reporting business segment in Hong Kong and Singapore, of which the majority of revenue is derived from Hong Kong.